Over the last several decades, our relationship with our animal companions has changed dramatically. They are now family members.

Two thirds of families in the United States have a pet, which translates to more than 60 million households with a dog and over 40 million households with a cat. In addition, 80% of those households say they care for their pets like children, creating an annual spend of over $75 billion, according to the American Pet Products Association.1 In fact, consumers spent $880 million on Valentine’s Day presents for their pets in 2018 and $1.5 billion on knee surgeries for dogs.

KindredBio is focused on bringing groundbreaking products and innovative new technologies to veterinary medicine, because we believe our animal companions deserve the same kinds of safe and effective medicines that human family members enjoy.

Our core strategy is to modify, improve, and repurpose pre-existing drugs and therapeutics that have already been proven safe and effective in humans. This approach allows us to leverage the billions of dollars of R&D that have been invested into human therapeutics, and quickly and efficiently develop innovative drugs for cats, dogs, and horses.

Our goal with this strategy is a 50 to 70% success rate, which greatly surpasses the norms in typical drug development of new chemical entities.  We develop our therapeutics for an average of $5 million to $8 million in only 3 to 6 years. The market for veterinary drugs may only be one tenth the size of the human market, but the cost of development is about 1/100th. This makes our ROI very attractive and is consistent with our mission of delivering favorable returns for our shareholders, while at the same time improving and saving the lives of cats, dogs, and horses.

1. Pet industry market size & ownership statistics. American pet products association. Available from: [Access Date: September 16, 2019]

US-CORP-1900172 OCT-19